The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.
What Market Size Increase Is Anticipated For The Human Serum Albumin Market Over The 2026–2030 Period?
The human serum albumin market size has experienced significant growth in recent years. It is anticipated to expand from $5.79 billion in 2025 to $6.21 billion in 2026, achieving a compound annual growth rate (CAGR) of 7.3%. The historical increase can be ascribed to factors including the limited availability of recombinant HSA, reliance on plasma-derived HSA, rising hospital and clinical demand, increasing utilization in diagnostic and therapeutic applications, and the adoption of standard injection solutions.
The human serum albumin market is projected for robust expansion in the coming years, with its size forecast to reach $8.16 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 7.0%. This anticipated growth is largely fueled by the advancements in yeast, bacterial, and plant-based recombinant hsa development, alongside an escalating demand for fatty acid-free formulations. Further contributions come from the broadening scope of drug delivery and nutrition enhancement applications, increased investment in research laboratories, and greater procurement by hospitals and blood banks. Key trends during this period are expected to encompass a surging demand for both plasma-derived and recombinant human serum albumin, a greater utilization of hsa in volume expanders and drug delivery systems, and an uptick in the adoption of lyophilized powder and injection solutions. Additionally, the market will observe an expansion of applications within hospitals and research laboratories, alongside a heightened focus on fatty acid-free and specialty hsa preparations.
Download the Free Sample Report to Explore Key Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=27310&type=smp
Which Major Factors Are Driving The Expansion Of The Human Serum Albumin Market?
The human serum albumin market is expected to grow due to the increasing incidence of liver diseases. These conditions involve a range of disorders that impair liver function, including hepatitis, fatty liver disease, cirrhosis, and liver cancer. The rise in liver diseases is attributed to the growing prevalence of obesity, as excess abdominal fat can lead to non-alcoholic fatty liver disease (NAFLD), causing fat accumulation, inflammation, and potential liver failure. Human serum albumin assists in managing liver disease by restoring blood volume, reducing fluid accumulation, protecting kidney function, and improving outcomes in complications such as ascites and hepatorenal syndrome. For instance, a report published in December 2024 by the Office for Health Improvement and Disparities, a UK-based government agency, revealed that premature deaths from alcoholic liver disease increased by 3.6% in 2023, reaching 5,984 cases compared with 5,776 in 2022. Therefore, the increasing prevalence of liver diseases is driving the growth of the human serum albumin market.
How Is The Human Serum Albumin Market Segmented Across Key Categories?
The human serum albumin market covered in this report is segmented –
1) By Type Of Preparation: Recombinant Human Serum Albumin, Plasma-Derived Human Serum Albumin
2) By Formulation Type: Injection Solutions, Lyophilized Powder
3) By Distribution Channel: Direct Sales, Online Pharmacies, Third-party Distributors, Hospital Pharmacies
4) By Application: Volume Expanders, Drug Delivery Systems, Nutrition Enhancement, Diagnostic Agents
5) By End-User: Hospitals, Research Laboratories, Pharmaceutical Companies, Blood Banks
Subsegments:
1) By Recombinant Human Serum Albumin: Yeast-Based Recombinant Human Serum Albumin, Bacterial-Based Recombinant Human Serum Albumin, Plant-Based Recombinant Human Serum Albumin, Mammalian Cell-Based Recombinant Human Serum Albumin, Insect Cell-Based Recombinant Human Serum Albumin
2) By Plasma-Derived Human Serum Albumin: 5% Human Serum Albumin Solution, 20% Human Serum Albumin Solution, 25% Human Serum Albumin Solution, Lyophilized Human Serum Albumin, Fatty Acid-Free Human Serum Albumin
Which Upcoming Trends Are Expected To Influence The Human Serum Albumin Market?
Companies operating in the human serum albumin market are prioritizing the creation of advanced solutions, such as animal-free recombinant excipients, to improve product safety, ensure scalability, and comply with regulatory requirements in biomanufacturing applications. An animal-free recombinant excipient is defined as a biologically engineered, inactive substance produced through recombinant DNA technology without any animal- or human-derived components, thereby guaranteeing high purity and safety in pharmaceutical and biomanufacturing uses. For example, in April 2025, InVitri Inc., a US-based supplier of animal-free, recombinant proteins and excipients, unveiled Optibumin 25, the first recombinant 25% human serum albumin specifically designed for closed-system biomanufacturing. This product is optimized for downstream processing, formulation, and cryopreservation workflows, and is presently available in 100 mL single-use bags. Its animal-origin-free and chemically defined composition ensures superior purity, consistency, and reduced contamination risks. Furthermore, it is GMP-ready, scalable to commercial production volumes, and offers a stable, sterile solution that integrates effortlessly into applications such as viral vector manufacturing, stem cell preservation, vaccine formulation, and regenerative medicine.
Who Are The Dominant Players Shaping The Human Serum Albumin Market Landscape?
Major companies operating in the human serum albumin market are Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, CSL Behring (CSL), Baxter International Inc., Grifols SA, Sartorius AG, Octapharma AG, Kedrion Biopharma, Shanghai RAAS Blood Products Co Ltd., Biotest Aktiengesellschaft, LFB Group, Hualan Biological Engineering Inc., Taibang Biologic Group, Kamada Ltd., InVitria Inc., Reliance Life Sciences, Bio Products Laboratory, Mitsubishi Tanabe Pharma, Sichuan Yuanda Shuyang Pharmaceutical Co Ltd.
Read the full human serum albumin market report here:
https://www.thebusinessresearchcompany.com/report/human-serum-albumin-global-market-report
Which Region Currently Holds The Largest Share Of The Human Serum Albumin Market?
North America was the largest region in the human serum albumin market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human serum albumin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Tailored Human Serum Albumin Market Research Report For Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=27310&type=smp
Browse Through More Reports Similar to the Global Human Serum Albumin Market 2026, By The Business Research Company
Wall Decor Market Report 2026
https://www.thebusinessresearchcompany.com/report/wall-decor-global-market-report
Painting And Wall Covering Contractors Market Report 2026
Commercial Flooring Market Report 2026
https://www.thebusinessresearchcompany.com/report/commercial-flooring-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model